Auscandoc<p>Pfizer’s <a href="https://med-mastodon.com/tags/RSVVaccine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RSVVaccine</span></a> for older adults, pregnant people approved by Health Canada - <a href="https://globalnews.ca/news/10203419/pfizer-rsv-vaccine-pregnant-people-health-canada/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">globalnews.ca/news/10203419/pf</span><span class="invisible">izer-rsv-vaccine-pregnant-people-health-canada/</span></a> “<a href="https://med-mastodon.com/tags/HealthCanada" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HealthCanada</span></a> on Thursday approved another respiratory syncytial virus (<a href="https://med-mastodon.com/tags/RSV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RSV</span></a>) vaccine for adults over the age of 60 and pregnant people.</p><p>Pfizer’s bivalent RSV vaccine, <a href="https://med-mastodon.com/tags/Abrysvo" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Abrysvo</span></a>, has been authorized for the use of pregnant individuals from 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease caused by RSV in <a href="https://med-mastodon.com/tags/infants" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>infants</span></a> from birth through six months”</p>